ITMCTR2000003252招募中4 期
Effect of Shexiang Tongxin Dropping Pill on Stable Coronary Artery Disease Patients with Normal Fractional Flow Reserve and Coronary Microvascular Disease
Sir Run Run Shaw Hospital (SRRSH), affiliated to Zhejiang University School of Medicine0 个研究点开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 80（—）
- 性别
- All
入选标准
- •Clinical inclusion criteria
- •1. Subjects with stable coronary artery disease,including chronic stable exertional angina,ischemic cardiomyopathy and stable course of disease after acute coronary syndrome (ACS)(The onset was more than 30 days and troponin was negative);
- •2. Subjects aged 18 to 80 years;
- •3. Women of childbearing age are not allowed to conceive or plan to conceive during the study period.Subjects are advised to use adequate contraceptive measures until (including) the end of follow-up;
- •4. Subjects must agree to a 12-month angiographic follow-up and 30-day, 6-month, 9-month, and 12-month clinical follow-up;
- •5. Subjects are able to understand the purpose of the study psychologically and linguistically, showing sufficient compliance to the research protocol;
- •6. By providing informed consent, the subjects acknowledge the risks and benefits described in the informed consent document.
- •Selection criteria for lesions: Coronary angiography shows stenosis >= 50% in at least one of the three main coronary arteries with FFR >= 0.80. No need for revascularization (including balloon inflation, stent implantation, coronary artery bypass grafting, etc.), IMR >= 25.
排除标准
- •Clinical exclusion criteria:
- •1. Subjects who have undergone revascularization within 12 months;
- •2. Subjects with severe congestive heart failure or severe heart failure(NYHA class IV);
- •3. Subjects with severe valvular heart disease;
- •4. Pregnant or breastfeeding women;
- •5. Subjects with a history of peptic ulcer or gastrointestinal bleeding in the past 6 months;
- •6. Subjects who suffered a stroke within 6 months before the operation;
- •7. Subjects with leukopenia (white blood cell count < 3*10^9/L for more than 3 days) or neutropenia (<1000 /mm3 for more than 3 days) or thrombocytopenia (<100,000/mm3);
- •8. Subjects with hemorrhagic constitution and contraindication to anticoagulants or antiplatelet drugs;
- •9. Subjects with a history of severe liver failure (ALT or AST exceeds 3 times the upper limit of normal (ULN));
- •10. Subjects with a history of severe renal failure(eGFR<30ml/min);
- •11. Subjects with heart transplant;
- •12. Subjects with cardiogenic shock;
- •13. Subjects with a left ventricular ejection fraction of less than 30%;
- •14. Subjects with a life expectancy of not more than 1 year or with difficulties in clinical follow-up;
- •15. Subjects who have previously taken Shexiang Tongxin Dropping Pill;
- •16. Subjects who are considered to be unsuitable by researchers for other reasons.
- •Exclusion criteria for lesions:
- •1. Thrombotic lesions;
- •2. Coronary spasm without significant stenosis;
- •3. Left main disease with a diameter stenosis rate of >= 50%;
- •4. Type C-F dissection of coronary artery.
研究者
相似试验
尚未招募
4 期
Effectiveness of Guanxinning Tablet on the Stable Coronary Artery Disease based on the Real World: A Multi-center Registration StudyITMCTR1900025340Xiyuan Hospital, CACMS
招募中
4 期
Effect of Guanxindanshen Dropping Pills on Quality of Life and Cardiovascular Prognosis of Patients with Depression or Anxiety after PCI for Coronary Heart DiseaseITMCTR1900002368Xiyuan Hospital, CACMS
尚未招募
4 期
Clinical study on the immediate of Shexiang Tongxin dropping pill on coronary slow blood flow and its long-term effectITMCTR2000003534Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine
招募中
4 期
The impact of compound Danshen dropping pills on ventricular remodeling and cardiac function after acute anterior wall myocardial infarction: a multicenter, randomized, double-blind, placebo-controlled clinical trialITMCTR2000003341The First Affiliated Hospital of Nanjing Medical University
尚未招募
1 期
Effect of Jiangtangxiaozhi Capsule on intestinal flora in obese IGT patientsImpaired glucose toleranceITMCTR2000003135Xiyuan Hospital,China Academy of Chinese Medical Sciences